Related Experiment Videos
Polymorphisms in the large subunit of human RNA polymerase II as target for allele-specific inhibition
A L ten Asbroek1, K Fluiter, M van Groenigen
1Neurozintuigen Laboratory, Academic Medical Center, PO Box 22700, 1000 DE Amsterdam, The Netherlands.
Abstract:
The lack of specificity of cancer treatment causes damage to normal cells as well, which limits the therapeutic range. To circumvent this problem one would need to use an absolute difference between normal cells and cancer cells as therapeutic target. Such a difference exists in the genome of all individuals suffering from a tumor that is characterized by loss of genetic material [loss of heterozygosity (LOH)]. Due to LOH, the tumor is hemizygous for a number of genes, whereas the normal cells of the individual are heterozygous for these genes. Theoretically, polymorphic sites in these genes can be utilized to selectively target the cancer cells with an antisense oligonucleotide, provided that it can discriminate the alleles and inhibit gene expression. Furthermore, the targeted gene should be essential for cell survival, and 50% gene expression sufficient for the cell to survive. This will allow selective killing of cancer cells without concomitant toxicity to normal cells. As an initial step in the experimental test of this putative selective cancer cell therapy, we have developed a set of antisense phosphorothioate oligonucleotides which can discriminate the two alleles of a polymorphic site in the gene encoding the large subunit of RNA polymerase II. Our data show that the exact position of the antisense oligonucleotide on the mRNA is of essential importance for the oligo-nucleotide to be an effective inhibitor of gene expression. Shifting the oligonucleotide position only a few bases along the mRNA sequence will completely abolish the inhibitory activity of the antisense oligonucleotide. Reducing the length of the oligonucleotides to 16 bases increases the allele specificity. This study shows that it is possible to design oligonucleotides that selectively target the matched allele, whereas the expression level of the mismatched allele, that differs by one nucleotide, is only slightly affected.
Insights
Researchers developed allele-specific antisense oligonucleotides to target cancer cells by exploiting loss of heterozygosity (LOH). This approach selectively inhibits gene expression in tumor cells, offering a potential new cancer therapy with reduced toxicity to normal cells.
Area of Science:
- Molecular Biology
- Cancer Therapeutics
- Oligonucleotide Design
Background:
- Current cancer treatments lack specificity, damaging normal cells and limiting therapeutic efficacy.
- Loss of heterozygosity (LOH) creates genetic differences between tumor and normal cells, presenting a potential therapeutic target.
- Antisense oligonucleotides (ASOs) offer a way to selectively target genes, but require allele discrimination for cancer therapy.
Purpose of the Study:
- To investigate the potential of allele-specific ASOs for selective cancer cell targeting.
- To develop and test ASOs that can discriminate between alleles in individuals with LOH.
- To identify optimal design parameters for effective and specific gene silencing in cancer.
Main Methods:
- Designed and synthesized antisense phosphorothioate oligonucleotides targeting a polymorphic site in the RNA polymerase II large subunit gene.
- Evaluated the allele specificity and gene silencing efficacy of ASOs with varying positions and lengths.
- Assessed the impact of ASO binding site on mRNA inhibition and allele discrimination.
Main Results:
- Developed ASOs capable of discriminating between alleles at a polymorphic site.
- Demonstrated that the exact position of the ASO on mRNA is critical for effective gene inhibition.
- Found that reducing ASO length to 16 bases enhanced allele specificity, with minimal impact on the mismatched allele.
Conclusions:
- It is feasible to design allele-specific antisense oligonucleotides for targeted cancer therapy.
- This approach leverages loss of heterozygosity to selectively inhibit cancer cell gene expression.
- Optimized ASO design, including precise positioning and length, is crucial for achieving high specificity and therapeutic potential.